Yohan Gerber-Ferder

Has grant

Centre Méditerranéen de Médecine Moléculaire
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Postdoctoral fellowship

Open Date: 2023-01-01

Close Date: 2026-01-01

Grant: Close

Extra thesis year

Open Date: 2021-10-01

Close Date: 2022-10-01

Grant: Close

Thesis

Open Date: 2018-10-01

Close Date: 2021-10-01

Articles (5)

Year:

2026

Year:

2025

T cells that recognize tumor antigens are crucial for mounting antitumor immune responses. Induction of antitumor T cells in immunogenic tumors depends on STING, the intracellular innate immune receptor for cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) and related cyclic dinucleotides (CDNs). However, the optimal way to leverage STING activation in nonimmunogenic tumors is still unclear. Here, we show that cGAMP delivery by intratumoral injection of virus-like particles (cGAMP-VLP) led to differentiation of circulating tumor-specific T cells, decreased tumor regulatory T cells (T regs ), and antitumoral responses that synergized with PD1 blockade. By contrast, intratumoral injection of the synthetic CDN ADU-S100 led to tumor necrosis and systemic T cell activation but simultaneously depleted immune cells from injected tumors and induced minimal priming of circulating tumor-specific T cells. The antitumor effects of cGAMP-VLP required type 1 conventional dendritic cells (cDC1), whereas ADU-S100 eliminated cDC1 from injected tumors. cGAMP-VLP preferentially targeted STING in dendritic cells at a 1000-fold smaller dose than ADU-S100. Subcutaneous administration of cGAMP-VLP showed synergy when combined with PD1 blockade or a tumor T reg -depleting antibody to elicit systemic tumor-specific T cells and antitumor activity, leading to complete and durable tumor eradication in the case of tumor T reg depletion. These findings show that cell targeting of STING stimulation shapes the antitumor T cell response and identify a therapeutic strategy to enhance T cell–targeted immunotherapy.

Year:

2023

Year:

2023

Year:

2023

Collaborators (13)

Judith C Sluimer

Maastricht University Medical Centre

NETHERLANDS
View details

Susanna Bodoy

Head of the Department

Universitat de Vic - Universitat Central de Catalunya

SPAIN
View details

Julie Helft

Group leader

Institut Cochin

FRANCE
View details

Erik Biessen

University of Maastricht

NETHERLANDS
View details

Nicolas Manel

PSL Research University

FRANCE
View details

Laurent Yvan-Charvet

2021 to present | Director of research DR1

INSERM

FRANCE
View details

Bernard Malissen

Researcher / CNRS Investigator (Directeur de Recherche de Classe Exceptionnelle)

CNRS

FRANCE
View details

Marc Dalod

Centre d'Immunologie Marseille-Luminy

FRANCE
View details

FREDERIC FIORE

Head of Genetic Engineering Department, PhD

INSERM Délégation régionale Provence Alpes Cote d'Azur et Corse

FRANCE
View details

Pierre Guermonprez

Institut Pasteur

FRANCE
View details

Sylvain BAULANDE

Head

Institut Curie

FRANCE
View details

Sébastien Dussaud

Sorbonne Université Campus Pierre et Marie Curie

FRANCE
View details

Caroline Hoffmann

-

FRANCE
View details